Abstract
Albumin polymeric Nanoparticles (NPs) have opened a great expectancy as for controlled drug delivery due to their therapeutic potency. Concomitantly biodegradable NPs technologies with target linked structures to pave the way of personalised medicine are becoming increasingly important in sight of a therapeutically effective research technology. This is particularly attractive for nanoparticle-based cancer delivery systems, based on the known limitations and efforts to overcome. This new group of gamma irradiated-NPs inherited both the protein delivery properties and robustness of polymer forming structures, and gamma irradiation techniques that leave clean, innocuous and biodegradable NPs.
These protein NPs made of serum albumin are referred to SA NPs that possesses several characteristics making them especially attractive to be considered as a drug delivery system. This review focused on methodologies actually being used in the synthesis and characterisation of albumin NPs and different author’s opinions on strategic ways to treat cancerous cell-lines with NPs. Utterly, challenges being overthrown by researchers are brought up to anneal an effective, all in one targeted albumin NPs to passed through in vitro and preclinical trials.
Keywords: Albumin, NPs, radiation-induced crosslinking, cancer cell-lines, therapeutic-drugs, desolvation.
Current Pharmaceutical Design
Title:Albumin Nanocarriers, γ - Irradiated Crosslinked, Combined with Therapeutic Drugs for Cancer Therapy
Volume: 23 Issue: 35
Author(s): Macarena Siri, Estefania Achilli, Mariano Grasselli and Silvia del V. Alonso*
Affiliation:
- Laboratorio de Biomembranas (LBM), Universidad Nacional de Quilmes. GBEyB, IMBICE-CONICET. Buenos Aires,Argentina
Keywords: Albumin, NPs, radiation-induced crosslinking, cancer cell-lines, therapeutic-drugs, desolvation.
Abstract: Albumin polymeric Nanoparticles (NPs) have opened a great expectancy as for controlled drug delivery due to their therapeutic potency. Concomitantly biodegradable NPs technologies with target linked structures to pave the way of personalised medicine are becoming increasingly important in sight of a therapeutically effective research technology. This is particularly attractive for nanoparticle-based cancer delivery systems, based on the known limitations and efforts to overcome. This new group of gamma irradiated-NPs inherited both the protein delivery properties and robustness of polymer forming structures, and gamma irradiation techniques that leave clean, innocuous and biodegradable NPs.
These protein NPs made of serum albumin are referred to SA NPs that possesses several characteristics making them especially attractive to be considered as a drug delivery system. This review focused on methodologies actually being used in the synthesis and characterisation of albumin NPs and different author’s opinions on strategic ways to treat cancerous cell-lines with NPs. Utterly, challenges being overthrown by researchers are brought up to anneal an effective, all in one targeted albumin NPs to passed through in vitro and preclinical trials.
Export Options
About this article
Cite this article as:
Siri Macarena , Achilli Estefania , Grasselli Mariano and del V. Alonso Silvia *, Albumin Nanocarriers, γ - Irradiated Crosslinked, Combined with Therapeutic Drugs for Cancer Therapy, Current Pharmaceutical Design 2017; 23 (35) . https://dx.doi.org/10.2174/1381612823666170615105909
DOI https://dx.doi.org/10.2174/1381612823666170615105909 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Future Approaches for Treating Hematologic Disease
Current Pharmaceutical Biotechnology Prevalence of Neuropathy Associated With Bortezomib: A Retrospective Study
Clinical Cancer Drugs Recent Advances in Medicinal Chemistry of Sulfonamides. Rational Design as Anti-Tumoral, Anti-Bacterial and Anti-Inflammatory Agents
Mini-Reviews in Medicinal Chemistry Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Involvement of the Transforming Growth Factor β in the Pathogenesis of Hereditary Hemorrhagic Telangiectasia
Current Pharmaceutical Design Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design New Cathepsin D Inhibitorswith Hydroxyethylamine Isosteres: Preparation and Characterization
Medicinal Chemistry Amrubicin: A Synthetic Anthracyclin Analogue in the Treatment of Extensive Stage Small Cell Lung Cancer
Recent Patents on Anti-Cancer Drug Discovery Elevated Microsatellite Alterations at Selected Tetranucleotide Repeats (EMAST) and Microsatellite Instability in Patients with Colorectal Cancer and Its Clinical Features
Current Molecular Medicine Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets
Current Medicinal Chemistry Timely Identification of Disease by Parallel Real-time Automated Processing of Huge Medical Databases of Images Distributed Geographically, through Knowledge Sharing
Current Bioinformatics Thymidine Phosphorylase: A Two-Face Janus in Anticancer Chemotherapy
Current Cancer Drug Targets Bioactive Peptides from Marine Organisms: A Short Overview
Protein & Peptide Letters The Evolution of Schizophrenia: A Model for Selection by Infection, with a Focus on NAD
Current Pharmaceutical Design Generation of Fusion Proteins for Selective Occlusion of Tumor Vessels
Current Drug Discovery Technologies Flavonoids in Atherosclerosis: An Overview of Their Mechanisms of Action
Current Medicinal Chemistry Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry Current Advances in the Identification and Characterization of Putative Drug and Vaccine Targets in the Bacterial Genomes
Current Topics in Medicinal Chemistry Polymersomes in Nanomedicine - A Review
Current Nanoscience Intracellular Chloride Channels: Critical Mediators of Cell Viability and Potential Targets for Cancer Therapy
Current Pharmaceutical Design